Search clinical trials for: interferon alpha 2b plus ribavirin

Total 1064 results

National Taiwan University Hospital
Schering-Plough

Completed

Interferon Alpha 2b Plus Ribavirin for Chronic Hepatitis B

Chronic Hepatitis B
National Institute of Allergy and Infectious Diseases...

Completed

Zidovudine Levels in HIV Infected Patients Being Treated for HCV

HIV Infections | Hepatitis C

Puerto Rico
Kyushu University

Unknown

PEG-IFN Plus Ribavirin Combination Therapy for Older Patients

Hepatitis C Virus

Japan
Junqi Niu
Chinese Academy of Sciences

Unknown

Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2) (sIFN-pred2)

Liver Diseases | Hepatitis C, Chronic | Interferon Deficiency

China
The First Hospital of Jilin University
Chinese Academy of Sciences

Unknown

Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred1)

Hepatitis

China
Bausch Health Americas, Inc.

Completed

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive

Chronic Hepatitis C
Ullevaal University Hospital
Schering-Plough

Completed

14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response

Hepatitis C Virus Infection

Norway
Brooke Army Medical Center
T.R.U.E. Research Foundation

Completed

Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC

Hepatitis C

United States
Amr Hafez
Ain Shams University

Completed

Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)

Hepatitis C | Hepatitis C, Chronic
MTI Medical Private Limited, Pakistan

Unknown

To Study the Efficacy and Safety of Renessans in Chronic HCV Patients

Hepatitis C, Chronic

Pakistan
HepNet Study House, German Liverfoundation
Hannover Medical School

Terminated

Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients (OPTEX2/3)

Hepatitis C, Chronic

Germany
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Rennes University Hospital

Completed

Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (BocepreVIH)

HIV-1 Infection | HCV Coinfection

France
Kyoto University

Completed

Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C

Hepatitis C, Chronic

Japan
Aga Khan University

Completed

Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders

Hepatitis C | Genotype 3 | Non-responders | Relapsers

Pakistan
Kyoto University

Completed

Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC

Hepatitis C, Chronic

Japan
Region Skane

Completed

Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy

Hepatitis C

Sweden
National Institute of Allergy and Infectious Diseases...

Terminated

Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

Hepatitis | HIV/AIDS

United States
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C

Chronic Hepatitis C

Taiwan
Digna Biotech S.L.

Completed

A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C

Chronic Hepatitis C Virus Infection | Genotype 1 | Treatment-Experienced Patients | Relapses

Spain
Ain Shams University
Schering-Plough; Tempus Labs; Fulbright; International Society for Infectious Diseases

Completed

Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4

Hepatitis C

Egypt
Merck Sharp & Dohme LLC

Completed

Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261) (SUPPORT)

Substance Abuse, Intravenous | Hepatitis C, Chronic
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

HIV Infections | Hepatitis C

United States, Puerto Rico
National Taiwan University Hospital
National Science Council, Taiwan

Unknown

Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan

Chronic Hepatitis C

Taiwan, Israel
Merck Sharp & Dohme LLC

Completed

Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)

Hepatitis C, Chronic
Centre hospitalier de l'Université de Montréal...
Hoffmann-La Roche; Centre de Recherche du Centre Hospitalier de l'Université...

Completed

Ribavirin Dose Optimization for the Treatment of Hepatitis C

Chronic Hepatitis C

Canada
ANRS, Emerging Infectious Diseases
Institut Pasteur

Withdrawn

Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C (ViZIR)

Chronic Hepatitis C

Egypt
Biolex Therapeutics, Inc.

Completed

Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV (SELECT-2)

Hepatitis C, Chronic

United States, Bulgaria, Puerto Rico, Romania
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)

Hepatitis C

Taiwan
ANRS, Emerging Infectious Diseases
Flamel Technologies

Unknown

Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4 (COAT IFN)

Chronic Hepatitis C

France
Casa Sollievo della Sofferenza IRCCS

Completed

Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3) (genotype-3)

Chronic Hepatitis

Italy
National Taiwan University Hospital
National Science Council, Taiwan; National Health Research Institutes, Taiwan

Unknown

Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta

Chronic Hepatitis B | Chronic Hepatitis D

Taiwan
Merck Sharp & Dohme LLC

Completed

Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)

Hepatitis C, Chronic
Center For Hepatitis C, Atlanta, GA

Completed

The SIM-SOF Trial for Hepatitis C

Chronic Hepatitis C

United States
National Taiwan University Hospital
National Science Council, Taiwan

Completed

Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients

Hepatitis C, Chronic

Taiwan
Merck Sharp & Dohme LLC

Completed

Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC
Bioikos Ambiente Srl

Completed

Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)

Hepatitis C
Kirby Institute
Merck Sharp & Dohme LLC

Completed

A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3 (ACTIVATE)

Hepatitis C, Chronic

Australia, Canada, United Kingdom, Belgium, Germany, Norway, Switzerland
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)

Hepatitis C, Chronic
Emory University
CURE Childhood Cancer, Inc.

Completed

Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

Juvenile Pilocytic Astrocytomas | Optic Pathway Gliomas

United States
Merck Sharp & Dohme LLC
Integrated Therapeutics Group

Withdrawn

Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371)

Liver Cirrhosis | HIV Infections | Hepatitis C
Merck Sharp & Dohme LLC

Completed

Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)

HIV Infections | Hepatitis C | HCV Infection
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Peripheral Blood Mononuclear Cell (PBMC) Gene Expression in HCV Genotype 1 Patients (PBMC)

Chronic Hepatitis C

Taiwan
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia

Essential Thrombocytopenia

China
The Wistar Institute
University of Pennsylvania; Merck Sharp & Dohme LLC

Completed

Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV

HIV-1 Infection

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Suspended

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Symptomatic COVID-19 Infection Laboratory-Confirmed

United States
Merck Sharp & Dohme LLC

Terminated

Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)

Hepatitis C | Hepatitis C, Chronic
French National Agency for Research on AIDS and...

Unknown

Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis

Fibrosis | Hepatitis C, Chronic

France

3

Subscribe